je.st
news
Peregrine Pharmaceuticals Announces Promising Bavituximab Phase I...
2015-03-31 22:46:43| Biotech - Topix.net
Peregrine Pharmaceuticals , today announced the peer-reviewed publication of clinical data from a Phase I investigator-sponsored trial evaluating the company's lead investigational immunotherapy bavituximab plus paclitaxel therapy in patients with HER2-negative metastatic breast cancer. The manuscript details the results of the Phase I trial showing that the combination produced an objective tumor response in 85% of patients, including 15% of these patients achieving a complete response, measured in accordance with Response Evaluation Criteria In Solid Tumors criteria.
Tags: phase
announces
promising
pharmaceuticals
Category:Biotechnology and Pharmaceuticals